Revenue qualityDanger
매출 흑자인데 영업CF 적자 (OCF/매출 -362%). 통계적 정황 신호이며 회계부정 단정이 아닙니다.
Xcell Therapeutics
373110 · KOSDAQ₩1,106-1.25%
2026-09-04 closeXcell Therapeutics last closed at ₩1,106 (-1.25%) on 2026-09-04. Listed on KOSDAQ; price, financials and dividends update daily after market close.
Loading chart…
Close
No active signal.
New high + volume — the real recordrecord · not a prediction
Last 30 sessions
303 picks
Next-day win rate
50.7%
Avg next-day
-0.11%
vs market
-0.49%p
Every new-high-plus-volume pick we actually published (Korea market) — not this stock alone.
Trade plan
Fill entry, stop, account size and risk percent to get a share count. The stop must sit below the entry.
A calculator · not advice or a guarantee
Financials & valuation at a glance
F
Overall: 건강관리 286/291 · top 98%
Factor composite · relative position in sector
Past reported results · not investment advice
More — deeper indicators
Financial safety
Reference indicatorAs of 2024Distress zoneFinancial-metric reference signal
Altman Z'' zoneZ'' -11.06
Distress
Grey
Safe
- Altman Z''
- -11.06
- Beneish M-Score
- —
- Sloan accrual
- -15.08%
Statistical flag unavailable
부실·조작 위험을 나타내는 사실 지표입니다. 투자 조언이 아니며, 검증 전이라 참고용입니다.
Factual information, not investment advice.
Earnings quality · Piotroski F-Score
1/9Weak
Piotroski measures year-over-year financial improvement, not absolute quality.
Financial improvement score1/9
Profitability
- Positive ROANot passed
- Positive OCFNot passed
- Improving ΔROANot passed
- Accruals (OCF > net income)Pass
Leverage & liquidity
- Lower debtNot passed
- Higher current ratioNot passed
- No new sharesNot passed
Efficiency
- Higher gross marginNot passed
- Higher asset turnoverNot passed
Calculation note: F7(신주)은 equity/asset 유지로 근사
Already-stable companies may score lower when year-over-year improvement is limited.
Factual information, not investment advice.
Forensic signals
Anomaly and structural signals observed in the financial statements.
Factual information, not investment advice.
Industry structure
KRAs of 2026-09-05건강관리
This stock is in 건강관리: revenue rank 276 of 287, share 0%.
276 / 2870%revenue share
Who dominates this industry?
- 1삼성바이오로직스7.3%
- 2셀트리온5.7%
- 3녹십자홀딩스3.5%
- 4유한양행3.3%
- 5대웅3.1%
- 6엑셀세라퓨틱스0%
Concentration
DistributedCR3 16.6%HHI and CR3 are separate industrial-organization facts; they are not the polarization verdict.
Polarization
Winner-take-all deepeningConsistentPolarization measures industry gaps and structure, not valuation, forecast, or investment advice.
Margin lens
- IQR%p
- 31.61
- Direction
- 확대
- Level
- 넓음
- Years
- 7
Value lens
- P90/P10
- 13.9
- Median P/B
- 1.47
- Level
- 넓음
- n
- 263
Survivorship note: 현재 산업 멤버십을 과거 연도에 소급 적용 — 과거 진입·퇴출 기업 미반영(복원 불가)
Factual information, not investment advice.
Risk sensitivity — adverse assumptions
Metric changes under stated assumptions; not a forecast or investment advice.
Base metrics
- Operating margin
- -482.2%
- Interest coverage
- -27.8x
- Return on equity (ROE)
- -104.6%
Operating margin −5pp
Operating lossInterest coverageBase -27.8x adverse case -28.1x
Return on equity (ROE)Base -104.6% adverse case -107%
Revenue −15%
Interest coverage riskInterest coverageBase -27.8x adverse case -23.7x
Return on equity (ROE)Base -104.6% adverse case -90.6%
Interest rate +2pp
Interest coverage riskInterest coverageBase -27.8x adverse case -19x
Return on equity (ROE)Base -104.6% adverse case -107.6%
Interest coverage limit
Already below the limit by 499.5ppInterest coverage limit at an operating margin of 17.3%
Interest expense coverage threshold
Key suppliers · Annual report
Annual reportDART · 2026-05-15Suppliers disclosed by the company in its 2026-05-15 annual report.
Suppliers without disclosed amount
GMPCellCorVTM
Who held it · filings
Filed recordA historical record from curated-guru 13F filings and DART 5%+ major-holding disclosures.
US 13F는 분기 공시이며 최대 45일 뒤 제출될 수 있습니다.
5%+ major-holding disclosures
- 이의일18.75%2026-04-01 · 증감 -0.79%p
Connections
AI-extracted related companies · for reference
Customers
Competitors
Same theme
바이오의약품세포·유전자치료제
Recent filings
Xcell Therapeutics's latest filings on Korea's DART. Open a headline for a reference summary and the original.
Source: DART (Korea electronic disclosure)
About Xcell Therapeutics
- What technical signals does Xcell Therapeutics (373110) have?
- Xcell Therapeutics current technical signals: no active technical signal.
- Is Xcell Therapeutics a cup-and-handle pattern?
- No. Xcell Therapeutics has no valid cup-and-handle signal right now.
- What are Xcell Therapeutics's financials and valuation?
- Xcell Therapeutics's income statement, balance sheet and cash flow are free for the most recent 8 years; the full history is on Pro. PER/PBR, dividend yield and sector valuation bands are free.
Like these rules? Backtest them.
Run this signal on this ticker in the free backtest builder — same window, no install.
Backtest this rule ↗Quantus Signal · live data · not investment advice · Privacy Policy